![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Newron Pharmaceuticals Raises 30 Million Euros
Newron Pharmaceuticals Raises 30 Million Euros
February 21, 2005
Newron Pharmaceuticals SpA, a research and development company focused on novel CNS therapies, announced the raising of EUR 30 million (fully committed), out of which EUR 23 million closed. The remaining EUR 7 million will remain open to additional interested parties for a few weeks. HBM Partners AG, on behalf of HBM BioCapital L.P. and HBM BioVentures Ltd., acted as lead investor. Existing investors, 3i Group, Apax Partners and Atlas Venture have all participated in the round.
BioSpace
(http://www.biospace.com/news_story.cfm?StoryID=19125520&full=1)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct